GSK
Biotech

GSK axes key cough drug candidate after phase 3 data disappoint

GSK ended development after delivering mixed phase 3 data, dealing a major blow to a potential blockbuster that analysts saw as a key catalyst.
Nick Paul Taylor Jul 17, 2026 5:46am
Takeda booth at AACR 2026

Takeda’s zasocitinib ‘top-notch’ for hard-to-treat psoriasis

Jul 16, 2026 6:00pm
Panther Rare Pharmacy

De-risking rare disease launches: precision beats scale

Brought to you by PANTHERx® Rare Pharmacy
Jennifer Doudna arriving at the laureates Get together at the Nobel Prize Museum in Stockholm on 6 December 2022

Nobel Laureate Jennifer Doudna enters AI protein design arena

Jul 16, 2026 2:00pm
chronic kidney disease money

Dimerix buys Mission’s kidney disease prospect in $292M deal

Jul 17, 2026 5:00am
Field of flowers with a rainbow behind

BlossomHill eyes IPO to grow taller in crowded cancer fields

Jul 17, 2026 12:08pm
More News

Jasper merges with Kira, while Tavneos rival sent to Mirador

Jul 17, 2026 9:54am

5 emerging biotech hubs

Jul 17, 2026 9:18am

Cue lines up new CMO and research head—Chutes & Ladders

Jul 17, 2026 8:30am

Axiom hopes it ‘solved 2 major potholes’ for stem cell biotechs

Jul 16, 2026 10:40am